<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11104556</article-id><article-id pub-id-type="pmc">2363456</article-id><article-id pub-id-type="pii">6691498</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1498</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Horwich</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Oliver</surname><given-names>R T D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilkinson</surname><given-names>P M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Mead</surname><given-names>G M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Harland</surname><given-names>S J</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Cullen</surname><given-names>M H</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Roberts</surname><given-names>J T</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Fossa</surname><given-names>S D</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Dearnaley</surname><given-names>D P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lallemand</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Stenning</surname><given-names>S P</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib></contrib-group><aff id="aff1"> <label>1</label>Radiotherapy Unit, Royal Marsden Hospital, Downs Rd, Sutton, Surrey</aff><aff id="aff2"> <label>2</label>School of Medicine, St Bartholomew's Hospital, West Smithfield, London</aff><aff id="aff3"> <label>3</label>Christie Hospital, Wilmslow Rd, Withington, Manchester</aff><aff id="aff4"> <label>4</label>Medical Oncology Dept, Royal South Hants Hospital, Brintons Terrace, Southampton</aff><aff id="aff5"> <label>5</label>Department of Oncology, Middlesex Hospital, Mortimer St, London, W1N 8AA</aff><aff id="aff6"> <label>6</label>Birmingham Oncology Centre, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH</aff><aff id="aff7"> <label>7</label>Northern Centre For Cancer Treatment, Newcastle General Hospital, Westgate Rd, Newcastle-upon-Tyne, NE4 6BE, UK</aff><aff id="aff8"> <label>8</label>Norwegian Radium Hospital, Montebello 0310, Oslo 3, Norway</aff><aff id="aff9"> <label>9</label>MRC Cancer Trials Office, 222 Euston Road, London, NW1 2DA, UK</aff><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>83</volume><issue>12</issue><fpage>1623</fpage><lpage>1629</lpage><history><date date-type="received"><day>31</day><month>03</month><year>2000</year></date><date date-type="rev-recd"><day>26</day><month>07</month><year>2000</year></date><date date-type="accepted"><day>15</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The UK Medical Research Council conducted this trial of carboplatin chemotherapy in advanced seminoma to compare single agent carboplatin with a standard combination of etoposide with cisplatin. The use of single agent carboplatin was expected to be associated with reduced toxicity. A total of 130 patients with advanced seminoma were randomly assigned to treatment with either single agent carboplatin (C) at a dose of 400 mg/m<sup>2</sup> to be corrected for glomerular filtration rate outside the range 81&#x02013;120 ml min<sup>&#x02013;1</sup> and to be administered on day 1 of a 21 day cycle to a total of 4 cycles or to etoposide + platinum (EP). The trial was designed as an equivalence study aiming to exclude a reduction in the 3-year progression-free survival in patients allocated to carboplatin of between 10 and 15&#x00025;, requiring initially a target accrual of 250 patients (90&#x00025; power significance level 5&#x00025; (one-sided)). The trial closed after 130 patients had been randomized following recommendation by an independent data monitoring committee. At a median follow-up time of 4.5 years, 81&#x00025; of patients had been followed up for at least 3 years and 19 patients have died. The estimated PFS rate (95&#x00025; Confidence Intervals (CI)) at 3 years was 71&#x00025; (60&#x02013;82&#x00025;) in patients allocated C and 81&#x00025; (71&#x02013;90&#x00025;) in those allocated EP; the 95&#x00025; CI for the difference in 3 year PFS was &#x02013;&#x02008;6&#x00025; to +19&#x00025;. The hazard ratio of 0.64 (95&#x00025; CI 0.32&#x02013;1.28) favoured EP but the difference was not statistically significant (log rank chi-squared = 1.59 <italic>P</italic> = 0.21). The 3-year survival rate was 84&#x00025; (75&#x02013;92&#x00025;) in those allocated C, and 89&#x00025; (81&#x02013;96&#x00025;) in those allocated EP. The hazard ratio for survival was 0.85 with 95&#x00025; CI, 0.35&#x02013;2.10, log rank chi-squared = 0.12, <italic>P</italic> = 0.73. The trial has not demonstrated statistically significant differences in the major survival endpoints comparing single agent carboplatin with a combination of etoposide + cisplatin. This cannot be taken as an indication of equivalence since the limited size of this trial rendered it unable to exclude a 19&#x00025; lower progression-free survival and survival in those treated with single agent carboplatin which would be important clinically. Standard initial chemotherapy for advanced seminoma should be based on cisplatin combinations and the role of carboplatin awaits the outcome of further studies. &#x000a9; 2000 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.org.uk">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>seminoma</kwd><kwd>germ cell tumour</kwd><kwd>chemotherapy</kwd><kwd>cisplatin</kwd><kwd>carboplatin</kwd><kwd>randomized control trial</kwd></kwd-group></article-meta></front></article>


